Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation: A novel clinical biomarker

Damien J. Lapar, Marie D. Burdick, Abbas Emaminia, David A. Harris, Brett A. Strieter, Ling Liu, Mark Robbins, Irving L. Kron, Robert M. Strieter, Christine L. Lau

Research output: Contribution to journalArticle

45 Scopus citations

Abstract

Background: Development of bronchiolitis obliterans syndrome (BOS) after lung transplantation confers increased patient morbidity and mortality. Fibrocytes are circulating bone marrowderived mesenchymal cell progenitors that influence tissue repair and fibrosis. Fibrocytes have been implicated in chronic pulmonary inflammatory processes. We investigated the correlation of circulating fibrocyte number with BOS development in lung transplant patients. Methods: We prospectively quantified circulating fibrocyte levels among lung transplant patients. Patients were stratified according to the development of BOS as indicated by predicted forced expiratory volume in 1 second. Fibrocyte activity was analyzed by flow cytometry (cluster of differentiation 45 +, collagen 1+) in a blinded manner related to clinical presentation. Results: Thirty-nine patients (61.5% men) underwent double (33.3%), left (25.6%), or right (41.0%) lung transplantation. Average patient age was similar between BOS and non-BOS patients (58.3 ± 3.9 vs 60.3 ± 2.0 years, p = 0.67). Chronic obstructive lung disease was the most common indication for lung transplantation (41.0%). Median forced expiratory volume in 1 second was lower among BOS patients compared with non-BOS patients (1.08 vs. 2.18 L/s, p = 0.001). Importantly, circulating fibrocyte numbers were increased in BOS patients compared with non-BOS patients (8.91 vs 2.96 × 105 cells/mL, p = 0.03) by flow cytometry and were incrementally increased with advancing BOS stage (p = 0.02). Conclusions: Increased circulating fibrocyte levels correlate with the development of BOS after lung transplantation and positively correlate with advancing BOS stage. Quantification of circulating fibrocytes could serve as a novel biomarker and possible therapeutic target for BOS development in lung transplant patients.

Original languageEnglish (US)
Pages (from-to)470-477
Number of pages8
JournalAnnals of Thoracic Surgery
Volume92
Issue number2
DOIs
StatePublished - Aug 1 2011
Externally publishedYes

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Circulating fibrocytes correlate with bronchiolitis obliterans syndrome development after lung transplantation: A novel clinical biomarker'. Together they form a unique fingerprint.

Cite this